| Citation: | ZHOU Yu, SONG Hongmei. Interpretation on the 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 271-277. doi: 10.12290/xhyxzz.2023-0043
|
| [1] | Masters SL, Simon A, Aksentijevich I, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)[J]. Annu Rev Immunol, 2009, 27: 621-68. doi: 10.1146/annurev.immunol.25.022106.141627 |
| [2] | Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations[J]. Otolaryngol Head Neck Surg, 2011, 145: 295-302. doi: 10.1177/0194599811402296 |
| [3] | Dollfus H, Hafner R, Hofmann HM, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood[J]. Arch Ophthalmol, 2000, 118: 1386-1392. doi: 10.1001/archopht.118.10.1386 |
| [4] | Hill SC, Namde M, Dwyer A, et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA)[J]. Pediatr Radiol, 2007, 37: 145-152. doi: 10.1007/s00247-006-0358-0 |
| [5] | Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes[J]. Arthritis Rheum, 2013, 65: 1116-1121. doi: 10.1002/art.37827 |
| [6] | Levy R, Gerard L, Kuemmerle-Deschner J, et al. Pheno-typic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry[J]. Ann Rheum Dis, 2015, 74: 2043-2049. |
| [7] | Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry[J]. Ann Rheum Dis, 2014, 73: 2160-2167. doi: 10.1136/annrheumdis-2013-204184 |
| [8] | Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever[J]. Ann Rheum Dis, 2016, 75: 644-651. doi: 10.1136/annrheumdis-2015-208690 |
| [9] | Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist[J]. Ann Rheum Dis, 2022, 81: 907-921. doi: 10.1136/annrheumdis-2021-221801 |
| [10] | Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Arthritis Rheumatol, 2022, 74: 1102-1121. doi: 10.1002/art.42139 |
| [11] | Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)[J]. Ann Rheum Dis, 2017, 76: 942-947. doi: 10.1136/annrheumdis-2016-209686 |
| [12] | Zhou Y, Wang W, Zhong L, et al. Clinical and genetic spectrum of 14 cases of NLRP3-associated autoinflammatory disease (NLRP3-AID) in China and a review of the literature[J]. Orphanet J Rare Dis, 2022, 17: 214. doi: 10.1186/s13023-022-02364-z |
| [13] | Sobolewska B, Angermair E, Deuter C, et al. NLRP3 A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms[J]. J Rheumatol, 2016, 43: 1101-1106. doi: 10.3899/jrheum.150681 |
| [14] | Kilic H, Sahin S, Duman C, et al. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome[J]. Eur J Paediatr Neurol, 2019, 23: 466-472. doi: 10.1016/j.ejpn.2019.03.006 |
| [15] | Li C, Tan X, Zhang J, et al. Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS)[J]. Sci China Life Sci, 2017, 60: 1436-1444. doi: 10.1007/s11427-017-9246-4 |
| [16] | Livneh A, Drenth JP, Klasen IS, et al. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: two diseases with distinct clinical, serologic, and genetic features[J]. J Rheumatol, 1997, 24: 1558-1563. |
| [17] | van der Hilst JCH, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome[J]. Medicine (Baltimore), 2008, 87: 301-310. doi: 10.1097/MD.0b013e318190cfb7 |
| [18] | Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, et al. Diagnostic Value of Urinary Mevalonic Acid Excretion in Patients with a Clinical Suspicion of Mevalonate Kinase Deficiency (MKD)[J]. JIMD Rep, 2016, 27: 33-38. |
| [19] | Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist[J]. JCI Insight, 2017, 2: e94838. doi: 10.1172/jci.insight.94838 |
| [20] | Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes[J]. Am J Hum Genet, 2002, 71: 198-203. doi: 10.1086/341357 |
| [21] | Mcdermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes[J]. Cell, 1999, 97: 133-144. doi: 10.1016/S0092-8674(00)80721-7 |
| [22] | D'osualdo A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever[J]. Eur J Hum Genet, 2005, 13: 314-320. doi: 10.1038/sj.ejhg.5201323 |
| [23] | Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist[J]. N Engl J Med, 2009, 360: 2426-2437. doi: 10.1056/NEJMoa0807865 |
| [24] | Rowczenio DM, Gomes SM, Arostegui JI, et al. Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience[J]. Front Immunol, 2017, 8: 1410. doi: 10.3389/fimmu.2017.01410 |
| [25] | Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anak-inra: a cohort study to determine three- and five-year outcomes[J]. Arthritis Rheum, 2012, 64: 2375-2386. doi: 10.1002/art.34409 |
| [26] | Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study[J]. Clin Ther, 2012, 34: 2091-2103. doi: 10.1016/j.clinthera.2012.09.009 |
| [27] | Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger[J]. Arthritis Rheumatol, 2019, 71: 1955-1963. doi: 10.1002/art.41004 |
| [28] | Piram M, Kone-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes[J]. Ann Rheum Dis, 2014, 73: 2168-2173. doi: 10.1136/annrheumdis-2013-203666 |
| [29] | Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations[J]. Br J Clin Pharmacol, 2015, 79: 395-404. doi: 10.1111/bcp.12267 |
| [30] | Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency[J]. Ann Rheum Dis, 2011, 70: 2155-2158. doi: 10.1136/ard.2011.149922 |
| [31] | Grimwood C, Despert V, Jeru I, et al. On-demand treatment with anakinra: a treatment option for selected TRAPS patients[J]. Rheumatology (Oxford), 2015, 54: 1749-1751. doi: 10.1093/rheumatology/kev111 |
| [32] | Rodriguez-Smith J, Lin YC, Tsai WL, et al. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation[J]. Arthritis Rheumatol, 2017, 69: 1325-1336. doi: 10.1002/art.40055 |
| [33] | Kuemmerle-Deschner JB, Welzel T, Hoertnagel K, et al. New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation[J]. Rheumatology (Oxford), 2020, 59: 3259-3263. doi: 10.1093/rheumatology/keaa119 |
| [34] | Papa R, Lane T, Minden K, et al. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry[J]. J Allergy Clin Immunol Pract, 2021, 9: 783-991. e4. doi: 10.1016/j.jaip.2020.10.053 |
| [35] | Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome[J]. Arthritis Care Res (Hoboken), 2017, 69: 578-586. doi: 10.1002/acr.23120 |
| [36] | Obici L, Meini A, Cattalini M, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis[J]. Ann Rheum Dis, 2011, 70: 1511-1512. doi: 10.1136/ard.2010.143438 |
| [37] | Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry[J]. Arthritis Rheumatol, 2016, 68: 2795-2805. doi: 10.1002/art.39763 |
| [38] | de Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes[J]. N Engl J Med, 2018, 378: 1908-1919. doi: 10.1056/NEJMoa1706314 |
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad: